World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
81
Citations
21961
World Ranking
1580
National Ranking
6

Medicine

D-Index
81
Citations
21963
World Ranking
16738
National Ranking
47

Eng Eong Ooi publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Eng Eong Ooi sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 376 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Eng Eong Ooi D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Eng Eong Ooi sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 81 D-Index — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Eng Eong Ooi is a researcher affiliated with the National University of Singapore in Singapore. Their scholarly work primarily focuses on medicine, with a significant emphasis on infectious diseases and related public health concerns. They have an extensive research portfolio that spans multiple subfields, including infectious diseases, public health, environmental and occupational health, molecular biology, epidemiology, and immunology.

Their research addresses several main topics, prominently including mosquito-borne diseases and control, viral infections and vectors, SARS-CoV-2 and COVID-19 research, COVID-19 clinical research studies, malaria research and control, viral infections and outbreaks research, and the long-term effects of COVID-19.

Eng Eong Ooi has contributed to numerous publications in a variety of scientific venues. Some of the frequent publication forums include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • SSRN Electronic Journal
  • EBioMedicine
  • Faculty Opinions - Post-Publication Peer Review of the Biomedical Literature
  • PLoS neglected tropical diseases

The following is a selection of recent papers authored by Eng Eong Ooi, listing the full title, publication year, and venue:

  • "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls" (2020, Nature)
  • "A Dynamic Immune Response Shapes COVID-19 Progression" (2020, Cell Host & Microbe)
  • "Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset" (2021, Med)
  • "A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice" (2021, Molecular Therapy)
  • "Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development" (2020, EBioMedicine)

Throughout their career, Eng Eong Ooi has frequently collaborated with several peers. Their frequent coauthors include:

  • Jenny G. Low
  • Kuan Rong Chan
  • Shirin Kalimuddin
  • Eugenia Z. Ong
  • Hwee Cheng Tan

Their research contributions are notable for intersecting clinical and molecular perspectives, especially in the context of infectious disease dynamics and immune responses. Their work on COVID-19 encompasses aspects related to immunity, vaccine efficacy, and the broader epidemiological understanding of the disease. They have published extensively on relevant viral infections and vector-borne diseases, reflecting a multidisciplinary approach to addressing public health challenges through both laboratory and clinical research methods.

Best Publications

  • SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

    Nina Le Bert;Anthony T Tan;Kamini Kunasegaran;Christine Y L Tham

  • Dengue prevention and 35 years of vector control in Singapore.

    Eng Eong Ooi;Kee Tai Goh;Duane J. Gubler

  • Etiology of severe non-malaria febrile illness in Northern Tanzania: a prospective cohort study.

    John A. Crump;Anne B. Morrissey;William L. Nicholson;Robert F. Massung

  • Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness

    Gayathri Manokaran;Esteban Finol;Esteban Finol;Chunling Wang;Jayantha Gunaratne;Jayantha Gunaratne

  • IL-1β, IL-6, and RANTES as Biomarkers of Chikungunya Severity

    Lisa F. P. Ng;Angela Chow;Yong-Jiang Sun;Dyan J. C. Kwek

  • Inhibition of SARS coronavirus infection with clinically approved antiviral drugs

    Emily Li Chuan Bukit Batok East Avenue Tan;Lawrence W. Stanton

  • Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness.

    Lukas B. Tanner;Mark Schreiber;Jenny G. H. Low;Adrian Ong

  • Seroepidemiology of Human Enterovirus 71, Singapore

    Eng-Eong Ooi;Meng-Chee Phoon;Baharudin Ishak;Soh-Ha Chan

  • A Dynamic Immune Response Shapes COVID-19 Progression.

    Eugenia Ziying Ong;Yvonne Fu Zi Chan;Wan Ying Leong;Natalie Mei Ying Lee

  • Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries

    Judit Barniol;Roger Gaczkowski;Eliana Vega Barbato;Rivaldo V da Cunha

  • Naturally acquired human Plasmodium knowlesi infection, Singapore.

    Oon Tek Ng;Eng Eong Ooi;Cheng Chuan Lee;Piao Jarrod Lee

  • Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention

    Eng-Eong Ooi;Eng-Eong Ooi;Duane J. Gubler;Duane J. Gubler

  • Update on Dengue: Epidemiology, Virus Evolution, Antiviral Drugs, and Vaccine Development

    Annelies Wilder-Smith;Eng Eong Ooi;Subhash G. Vasudevan;Duane J. Gubler

  • Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.

    Jenny G Low;Cynthia Sung;Limin Wijaya;Yuan Wei

  • The Structural Basis for Serotype-Specific Neutralization of Dengue Virus by a Human Antibody

    Ee Ping Teoh;Petra Kukkaro;En Wei Teo;Angeline P.C. Lim

  • Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial.

    Nicholas I Paton;Lawrence Lee;Ying Xu;Eng Eong Ooi;Eng Eong Ooi

  • Dengue virus activates cGAS through the release of mitochondrial DNA

    Bo Sun;Bo Sun;Karin B. Sundström;Jun Jie Chew;Pradeep Bist

  • Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset.

    Shirin Kalimuddin;Shirin Kalimuddin;Christine Y.L. Tham;Martin Qui;Ruklanthi de Alwis

  • Current Status of Dengue Therapeutics Research and Development.

    Jenny Guek Hong Low;Eng Eong Ooi;Subhash G. Vasudevan

  • The 5′ and 3′ Untranslated Regions of the Flaviviral Genome

    Wy Ching Ng;Ruben Soto-Acosta;Shelton S. Bradrick;Mariano A. Garcia-Blanco

  • A novel severe acute respiratory syndrome coronavirus protein, U274, is transported to the cell surface and undergoes endocytosis

    Yee Joo Tan;Eileen Teng;Shuo Shen;Timothy H.P. Tan

  • Early Dengue infection and outcome study (EDEN) - study design and preliminary findings.

    Jenny G. H. Low;Eng-Eong Ooi;Thomas Tolfvenstam;Yee-Sin Leo

  • Dengue and dengue hemorrhagic fever.

    D. J. Gubler;E. E. Ooi;S. Vasudevan;J. Farrar

Frequent Co-Authors

Yee Sin Leo
Yee Sin Leo Nanyang Technological University
Subhash G. Vasudevan
Subhash G. Vasudevan Australian National University
Duane J. Gubler
Duane J. Gubler Duke NUS Graduate Medical School
Martin L. Hibberd
Martin L. Hibberd London School of Hygiene & Tropical Medicine
David C. Lye
David C. Lye Tan Tock Seng Hospital
Antonio Bertoletti
Antonio Bertoletti Duke NUS Graduate Medical School
Sylvie Alonso
Sylvie Alonso National University of Singapore
Lee Ching Ng
Lee Ching Ng National Environment Agency

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to a variety of healthcare and research careers, especially in nursing and specialized practitioner roles. For those interested in nursing, exploring the easiest lpn programs to get into online can provide a supportive entry point into the medical field, combining practical skills with foundational health science knowledge.

Advancing further, many students find value in enrolling in the easiest online nurse practitioner programs. These programs offer flexibility and streamlined curricula to prepare candidates for advanced clinical roles, aligning well with the specialized knowledge required in immunology-related healthcare positions.

For those focusing on mental health, the best pmhnp programs online are critical, as they combine strong academic support with practical clinical placements. This ensures that graduates are well-prepared for real-world challenges in psychiatric nursing, an area closely linked to immune system function and neuroimmunology.

Cost is also a significant factor in choosing a program. Fortunately, there are affordable pmhnp programs that maintain high standards without burdening students with excessive debt, making specialized education more accessible for aspiring healthcare professionals.

Best Scientists Citing Eng Eong Ooi

Trending Scientists

Recently Published Articles